Aortic Stent Grafts Market | Revenue, Demand, Supply and Forecast

Market Summary and Growth Forecast

The global Aortic Stent Grafts Market is estimated at $3,750 million in 2026 and is expected to reach $7,050 million by 2035, growing at a CAGR of 7.3%.

Aortic stent grafts are implantable endovascular devices used to isolate weakened or damaged sections of the aorta from blood pressure. A typical system combines a metallic support frame with a synthetic graft covering. It is delivered through the vascular system and deployed inside the aorta. The objective is straightforward: create a new pathway for blood flow while reducing pressure on an aneurysm, dissection, ulcer, or traumatic lesion.

The market covers standard abdominal endovascular aneurysm repair systems, thoracic endovascular repair systems, and more complex fenestrated or branched platforms. It also includes modular limbs, cuffs, branch components, and delivery systems when supplied as part of the aortic repair platform. Surgical vascular grafts, coronary stents, peripheral covered stents sold for non-aortic use, and transcatheter heart valves are excluded.

Global Market Forecast

Note: Values are analyst estimates. The model uses addressable EVAR and TEVAR procedure volumes, complex-repair adoption, regional implant pricing, modular component use, and anticipated device approval cycles.

Why the Market Matters Commercially

Aortic stent grafts sit in a high-value part of the cardiovascular device industry. The buying decision is not based only on the price of the primary implant. Hospitals also evaluate anatomical coverage, component availability, delivery profile, physician familiarity, long-term clinical evidence, and emergency inventory support.

For suppliers, the Aortic Stent Grafts Market creates revenue through complete procedural systems rather than a single implant. A standard abdominal procedure may require a main body, contralateral limb, extensions, cuffs, introducers, guidewires, and closure devices. Complex thoracoabdominal procedures can require multiple branch components and considerably more pre-procedure planning. So, revenue per case rises as treatment moves from standard anatomy toward branched and fenestrated repair.

The business outlook through 2035 will be shaped by four structural forces.

Expansion of Endovascular Treatment

Endovascular aneurysm repair avoids a large abdominal or thoracic incision. That makes it particularly relevant for older patients and people considered unsuitable for open repair. Standard EVAR is already established for many infrarenal abdominal aneurysms. The next commercial frontier is more difficult anatomy involving renal arteries, visceral branches, the aortic arch, and the ascending aorta.

The U.S. FDA approved an off-the-shelf thoracoabdominal branched endoprosthesis in January 2024 for selected thoracoabdominal and pararenal aneurysms. The approved system uses an aortic component, branch components, a distal bifurcated component, and iliac extensions. This illustrates how the revenue pool is moving toward multi-component platforms rather than isolated stent grafts.

Aging Patient Base and Screening

Most repair demand is associated with aneurysmal disease, aortic dissection, penetrating aortic ulcers, and traumatic injury. Aging populations increase the number of people entering the clinical risk pool. Screening also affects procedure volumes because many aneurysms remain asymptomatic until detected through imaging.

In the United States, Medicare covers a one-time abdominal aortic aneurysm ultrasound for eligible at-risk beneficiaries. CMS updated related screening coding guidance in 2026, reinforcing the role of organized detection in moving patients into surveillance and, when indicated, repair pathways.

Regulatory Evidence Requirements

These products are permanent implants used in high-risk anatomy. Approval therefore depends on clinical evidence, mechanical testing, delivery accuracy, fatigue performance, sealing integrity, branch patency, and long-term follow-up.

The FDA can require post-approval studies to monitor continued safety and effectiveness. Several abdominal and thoracic stent graft platforms remain subject to ongoing long-term studies. The European MDR also requires tighter clinical evaluation and post-market follow-up for implantable and Class III devices. Periodic safety reporting must generally be updated at least annually for Class IIb and Class III devices.

This raises development costs. Yet it also creates a barrier to entry. New suppliers need clinical infrastructure, regulatory expertise, physician training programs, and years of follow-up data. A technically functional device alone is not enough.

Specialized Production and Inventory Management

Aortic graft production requires precise integration of metallic stent frameworks, graft fabric, radiopaque markers, sutures, and catheter-based delivery systems. Common materials include nitinol, stainless steel, expanded polytetrafluoroethylene, and polyester-based vascular fabrics. Material selection affects radial force, conformability, fatigue resistance, sealing, delivery profile, and visibility under fluoroscopy. FDA documentation for recent complex graft systems also shows the extensive durability, nickel-leachability, component-separation, and deployment-accuracy testing required before commercialization.

Manufacturing is further complicated by the number of diameters, lengths, tapers, limbs, branches, and extensions required. Hospitals cannot stock every configuration. Suppliers with responsive inventory systems, case-planning support, and emergency delivery capabilities can therefore defend market share even when competing products appear technically similar.

Key Consumers and Clients

The principal buyers and clinical users include:

• Tertiary and academic hospitals performing complex vascular procedures
• Specialty cardiovascular hospitals with vascular surgery and cardiac surgery programs
• Regional hospitals equipped for standard EVAR and selected TEVAR procedures
• Vascular surgeons responsible for patient selection and device deployment
• Interventional radiologists and interventional cardiologists participating in endovascular repair teams
• Cardiothoracic surgeons treating thoracic, arch, and hybrid aortic disease
• Public health systems and hospital procurement groups negotiating implant contracts
• Private hospital chains and group purchasing organizations managing system-wide device formularies
• Medical-device distributors serving markets without direct manufacturer coverage
• Clinical research centers participating in investigational device studies

Expert view: The largest commercial gain won’t come from routine price increases. It will come from treating anatomies that previously required open surgery or had no practical repair option. That changes both the number of eligible patients and the value generated per procedure.

Market Segmentation and Forecast Scope

The Aortic Stent Grafts Market should be segmented according to repair architecture, clinical indication, end-user setting, and geography. This structure avoids mixing standard EVAR systems with complex branch-preserving technologies. It also supports procedure-based revenue modelling.

By Repair Architecture

Standard Abdominal EVAR Systems

These systems are designed mainly for infrarenal abdominal aortic aneurysms with an adequate proximal sealing zone below the renal arteries. Most products use a bifurcated main body with modular iliac limbs.

Standard abdominal systems are estimated to account for 55.0% of global revenue in 2026. This is the first of only two segment shares disclosed in this section.

The segment remains the largest because standard EVAR is widely available and supported by established physician experience. Growth will be moderate rather than slow. Demand will continue through replacement of older platforms, lower-profile delivery systems, expanded anatomical indications, and increased procedure access in developing healthcare markets.

Standard Thoracic TEVAR Systems

Thoracic systems treat descending thoracic aneurysms, dissections, traumatic injuries, penetrating ulcers, and related lesions where the supra-aortic branches do not require direct incorporation into the graft.

Design priorities include conformability across the curved thoracic aorta, controlled deployment, resistance to migration, and accurate positioning near major branches. Demand is supported by both scheduled procedures and urgent cases.

Fenestrated and Branched Complex Aortic Systems

This category includes platforms designed to preserve blood flow to renal and visceral vessels during repair of juxtarenal, pararenal, suprarenal, and thoracoabdominal disease. Patient-specific fenestrated devices and off-the-shelf branched systems are included.

This is expected to be the fastest-growing product category, with an estimated 2026–2035 CAGR of 10.5%–11.5%. The segment benefits from higher revenue per procedure and a widening pool of anatomically eligible patients. However, growth depends on specialist training, regulatory approvals, bridging-stent availability, advanced imaging, and concentration of procedures in experienced centers.

Aortic Arch and Ascending Endovascular Systems

These systems are designed for lesions involving the arch or adjacent ascending aorta. They may use branched, modular, or hybrid configurations to maintain blood flow to cerebral vessels.

This is currently a smaller commercial category. Still, it is strategically important. The FDA approved the NEXUS aortic arch stent graft system in April 2026 for endovascular treatment of chronic dissections involving the arch in selected high-risk patients with appropriate anatomy. The approval creates a clearer U.S. commercialization route for aortic arch endografts.

By Clinical Application

Abdominal Aortic Aneurysm

This includes infrarenal abdominal aneurysms suitable for standard EVAR. It represents the core procedure base because of established screening pathways, standardized device sizing, and broad physician familiarity.

Thoracic Aortic Aneurysm

This includes aneurysmal disease of the descending thoracic aorta treated using standard thoracic endografts. Product choice is influenced by vessel diameter, landing-zone length, tortuosity, access-vessel size, and proximity to supra-aortic branches.

Thoracoabdominal, Pararenal and Juxtarenal Aneurysm

These cases involve or approach major branch vessels. They require fenestrated, branched, physician-modified, hybrid, or staged repair strategies.

This is one of the most attractive applications commercially. The procedure uses more components and needs extensive planning. Yet the eligible population is limited by anatomy, renal function, physician expertise, and access to specialized centers.

Aortic Dissection and Related Acute Aortic Syndromes

This category covers acute and chronic dissections, selected intramural hematomas, and penetrating atherosclerotic ulcers. The primary indication assigned at the time of treatment should determine revenue allocation to avoid double counting.

Chronic dissection is becoming particularly strategic as manufacturers develop devices that address both the proximal tear and continued false-lumen perfusion.

Traumatic Aortic Injury and Other Lesions

This segment includes blunt thoracic aortic injury, pseudoaneurysm, rupture, and selected emergency indications. Demand is lower in volume but clinically urgent. Hospitals value immediate device availability and a broad size matrix in these cases.

By End User

Academic and Tertiary Referral Hospitals

These facilities lead complex endovascular adoption. They typically maintain hybrid operating rooms, advanced imaging, intensive care support, vascular surgery teams, and clinical-trial capabilities.

Fenestrated, branched, thoracoabdominal, and arch procedures will remain concentrated in this segment through much of the forecast period.

Community and Regional Hospitals

These hospitals mainly perform standard infrarenal EVAR and selected descending-thoracic procedures. Growth depends on trained specialists, local procedure volumes, imaging capability, and referral economics.

Suppliers often compete here through ease of use, familiar deployment workflows, technical case support, and reliable inventory rather than through the most complex device architecture.

Specialty Heart and Vascular Hospitals

Specialty centers can generate high procedure throughput and structured referral networks. Their procurement decisions are often driven by clinical outcomes, standardized physician preference, inventory rationalization, and negotiated system pricing.

By Region

North America

North America is estimated to account for 40.5% of global revenue in 2026. This is the second disclosed segment share.

The region benefits from established reimbursement, a large treated population, clinical registries, strong physician training, and comparatively early access to new platforms. Its revenue share is also supported by higher implant prices and the increasing availability of complex endovascular systems.

Europe

Europe has a mature endovascular practice base and a strong network of specialist aortic centers. Several customized and complex technologies have historically entered selected European markets before broader U.S. commercialization.

The main constraints are country-level reimbursement differences, MDR evidence requirements, hospital budget pressure, and uneven access to complex repair outside leading centers.

Asia Pacific

Asia Pacific is expected to be the fastest-growing geographic market, with an estimated 2026–2035 CAGR of 8.5%–9.2%. China, Japan, South Korea, Australia, and selected Southeast Asian markets will account for most regional growth.

Japan already has advanced vascular care and an older population. China offers a larger expansion opportunity as cardiovascular centers, imaging capacity, and locally developed endovascular technologies scale. Pricing will remain lower than in the United States, so procedure growth may outpace revenue growth.

Latin America, Middle East and Africa — LAMEA

LAMEA includes a mix of established private cardiovascular centers and underpenetrated public healthcare systems. Brazil, Mexico, Saudi Arabia, the United Arab Emirates, South Africa, and selected urban markets will generate most near-term demand.

The main limiting factors are product affordability, specialist availability, reimbursement gaps, and dependence on imported devices. Standard EVAR will account for most procedures. Complex aortic repair will remain concentrated in a limited number of referral institutions.

Recommended Forecast Framework

This Aortic Stent Grafts Market forecast should count the complete implant configuration used in each procedure. Modular limbs, extensions, and branch components must be allocated to the parent repair architecture. They should not be counted again as a separate standalone market.

Use case: A thoracoabdominal procedure using one branched aortic component, four bridging components, an abdominal bifurcated component, and iliac extensions should be classified once under fenestrated and branched complex systems. Its full implant revenue is assigned to that procedure category.

Expert view: Standard abdominal EVAR will remain the revenue anchor. Still, complex grafts will contribute a disproportionate share of incremental value. They combine faster procedure growth, higher system prices, and greater dependence on manufacturer planning support.

Market Trends and Innovation Landscape

Innovation in the Aortic Stent Grafts Market is moving away from basic aneurysm exclusion and toward precise repair across increasingly difficult anatomy. The competitive question is no longer simply whether a graft can seal an aneurysm. Manufacturers must show that the system can be delivered through smaller access vessels, positioned accurately, preserve branch flow, tolerate long-term aortic movement, and simplify procedures that currently require extensive customization.

Expansion into Complex Aortic Anatomy

The most important R&D direction is the expansion of endovascular repair into pararenal, thoracoabdominal, arch, and selected ascending-aortic disease.

Historically, many of these patients required open surgery or highly customized treatment. Newer systems use fenestrations, branches, portals, modular components, and staged configurations to preserve blood flow to the kidneys, intestines, liver, and brain.

The FDA approval of W. L. Gore & Associates’ thoracoabdominal branch system in January 2024 marked an important commercial step. The device is designed for aneurysms extending into the visceral segment and uses four portals to connect the aortic graft with target branches. FDA-required testing included simulated fatigue, migration, sealing, branch flow, pressure drop, radiopacity, and modular separation.

In April 2026, the FDA approved Endospan’s aortic arch system for selected high-risk patients with chronic arch dissection. The approval indicates that arch repair is moving from a limited investigational field toward a defined commercial device category.

Shift from Custom-Made to Off-the-Shelf Platforms

Custom fenestrated grafts remain useful because they can be designed around individual anatomy. But manufacturing lead time limits their suitability for urgent cases. They also require detailed planning and tightly controlled production.

So, manufacturers are working on off-the-shelf branched platforms that can fit a broader range of anatomies. These devices could shorten treatment delays and expand access outside a small number of custom-device centers.

The trade-off is design complexity. An off-the-shelf system must accommodate anatomical variation without compromising seal, branch alignment, or vessel patency. This places greater emphasis on modularity, multiple size configurations, flexible delivery, and procedural training.

Lower-Profile and More Controlled Delivery Systems

Access-vessel limitations remain a practical reason why some patients cannot receive endovascular repair. Smaller delivery profiles can reduce the size of the arterial access required. This may allow treatment of patients with narrow, calcified, or tortuous iliac vessels.

The next generation of systems will also compete on deployment control. Physicians want the ability to position the graft accurately, make controlled adjustments, preserve branch access, and avoid unintended movement during release.

That said, a smaller delivery system cannot come at the expense of graft durability or radial support. Manufacturers must balance profile reduction with fabric thickness, stent geometry, catheter strength, and resistance to deformation.

Material and Structural Engineering

Most innovation is incremental rather than based on entirely new biomaterials. Nitinol remains important because of its shape-memory and self-expanding behavior. Stainless steel is used in selected structural and fixation components. Graft coverings commonly use ePTFE or woven polyester-type materials.

Current development work focuses on how these materials are configured. Key areas include:

• Thinner graft coverings that support smaller delivery profiles
• Improved conformability in curved or angulated anatomy
• Better fatigue resistance under continuous pulsatile loading
• Stronger modular junctions to reduce component separation risk
• Enhanced sealing zones for short or irregular vessel necks
• Optimized radiopaque markers for more accurate fluoroscopic positioning
• Reinforced branch interfaces for complex multi-component repairs

The approved thoracoabdominal branch platform reviewed by the FDA includes ePTFE, fluorinated ethylene propylene, nitinol, stainless steel, and radiopaque materials. Its regulatory testing demonstrates that material performance is evaluated as a complete mechanical system rather than as isolated components.

Imaging, Digital Planning and Selective AI Use

Pre-procedure CT angiography is central to device sizing and case planning. Physicians need accurate measurements of vessel diameter, centerline length, branch position, landing zones, calcification, thrombus, and access anatomy.

Planning software is increasingly used to generate centerlines, three-dimensional reconstructions, and recommended device dimensions. Image fusion can also overlay preoperative CT information onto live fluoroscopy during complex repair.

AI has a supporting role rather than a direct implant role. Research published in 2025 demonstrated that deep-learning systems can perform rapid aorto-iliac and thoracic-aortic segmentation. Other studies are assessing AI models for predicting outcomes after elective EVAR. These applications may reduce manual measurement time and standardize case review, but they remain adjunctive tools and require clinical validation.

Expert view: AI won’t replace the vascular surgeon’s planning decision. Its nearer-term value is in automating repetitive image measurements, identifying anatomical constraints, and flagging cases that need deeper review.

Personalized and 3D-Assisted Procedure Planning

Complex graft selection often requires collaboration among physicians, imaging specialists, and manufacturer case-planning teams. Three-dimensional anatomical models and virtual simulations can help teams understand branch orientation and select access strategies.

Use case: For a patient with a juxtarenal aneurysm, a planning team can reconstruct the aorta from CT data, map both renal arteries and the superior mesenteric artery, and test whether a proposed fenestrated configuration provides adequate sealing without blocking branch flow.

These tools are most valuable in high-complexity cases. Routine infrarenal EVAR will continue to rely on more standardized sizing workflows.

Clinical Evidence and Long-Term Durability

The market is entering a phase where long-term outcomes matter as much as procedural success. Hospitals and regulators are paying closer attention to endoleaks, migration, branch patency, aneurysm-sac behavior, reintervention, renal outcomes, and device integrity.

Post-approval surveillance remains active for several aortic platforms. For example, FDA databases list ongoing studies for abdominal, thoracic, conformable, branched, and arch systems. This evidence can influence label expansions, hospital adoption, and competitive positioning.

Products with reliable long-term data may gain preference even when competing systems offer a lower delivery profile or broader initial anatomical eligibility.

Recent Partnerships, Approvals and Corporate Activity

1. L. Gore & Associates — Complex Aortic Approval

In January 2024, the FDA approved the company’s thoracoabdominal branch endoprosthesis for selected thoracoabdominal and high-surgical-risk pararenal aneurysms. This created a commercially available off-the-shelf U.S. option for a category previously served largely by open, custom, or investigational approaches.

Medtronic — Expanded Ruptured-AAA Labeling

In October 2025, Medtronic announced FDA labeling approval removing a previous warning concerning treatment of ruptured abdominal aortic aneurysms from its established abdominal stent graft platform. The development strengthens the role of labeled clinical evidence in emergency-use positioning.

Terumo Aortic and Getinge — Fenestrated IDE Collaboration

In November 2025, Terumo Aortic enrolled the first patient in a U.S. pivotal IDE study of its fenestrated abdominal graft for juxtarenal and suprarenal aneurysms. Getinge’s covered bridging stent is being used in the study. Up to 45 sites and approximately 210 patients are planned, with follow-up extending for five years.

The collaboration shows that complex repair platforms depend on compatibility among the main aortic graft, bridging components, delivery tools, imaging, and physician training.

Artivion and Endospan — Aortic Arch Consolidation

Following FDA approval of the NEXUS arch system in April 2026, Artivion completed its acquisition of Endospan in May 2026. The upfront net purchase price was reported at $135 million, with additional consideration linked to commercial performance. Artivion had already distributed the platform in parts of Europe and acquired the underlying arch technology to expand its aortic portfolio.

This transaction indicates that aortic arch repair is becoming strategically valuable enough to support dedicated platform acquisitions rather than licensing agreements alone.

Innovation Outlook Through 2035

The most commercially important innovations will be those that expand eligibility without making procedures impractical. Four themes are likely to define product competition:

1. Off-the-shelf branched and fenestrated systems for complex aneurysms
2. Dedicated arch and ascending-aortic platforms for patients at high surgical risk
3. Lower-profile delivery with improved deployment control
4. Integrated planning, imaging, training, and clinical-support services

Expert view: By 2035, the Aortic Stent Grafts Market will be less defined by standard abdominal graft competition and more by how effectively suppliers manage the entire complex-repair pathway. Device architecture will remain central. But planning software, component compatibility, clinical evidence, inventory support, and physician training will increasingly decide which platform wins.

Competitive Intelligence and Benchmarking

Competition in the Aortic Stent Grafts Market is concentrated among a small group of vascular-device companies with established regulatory approvals, implant manufacturing capacity, physician-training programs, and long-term clinical evidence.

The competitive gap is widening between suppliers that mainly serve standard abdominal aneurysm repair and those that can address the thoracic, thoracoabdominal, iliac, and aortic arch regions. Product breadth matters. So does case-planning support. Complex procedures often require several compatible graft components rather than one implant.

Medtronic

Medtronic holds a strong global position in conventional endovascular aortic repair. Its portfolio covers modular abdominal systems, thoracic grafts, iliac extensions, introducer sheaths, and supporting balloon catheters. The company serves both standard and challenging anatomy across EVAR and TEVAR procedures.

Its competitive strength comes from a large installed physician base, extensive hospital contracting relationships, and broad international distribution. Hospitals familiar with its deployment workflow can standardize purchasing across abdominal and descending thoracic procedures.

The company’s principal strategic challenge is the growing importance of branched thoracoabdominal and arch repair. Competitors with approved off-the-shelf branch-preserving platforms may gain a larger share of complex cases.

Expert view: Medtronic’s commercial advantage remains scale and procedural familiarity. Its future position will depend on how quickly it expands from established EVAR and TEVAR categories into more complex branch-preserving repair.

L. Gore & Associates

L. Gore & Associates has one of the broadest endovascular aortic portfolios. It competes in abdominal aneurysm repair, descending thoracic repair, branched thoracic treatment, and off-the-shelf thoracoabdominal repair. Its product architecture is supported by expanded-polytetrafluoroethylene material expertise and a strong record in vascular implants.

The company has strengthened its position in complex aortic treatment through systems that preserve flow to an arch branch or visceral arteries. This gives it exposure to procedures with higher component use and greater revenue per patient.

Gore also competes through clinical support. Complex cases need detailed CT assessment, component selection, physician education, and procedural coordination. These services can create stronger hospital loyalty than device pricing alone.

Its current position can be described as a global technology leader with particular strength in complex thoracic and thoracoabdominal intervention.

Cook Medical

Cook Medical is an established specialist in modular aortic intervention. Its portfolio covers standard abdominal repair, fenestrated abdominal repair, thoracic grafting, iliac branch preservation, and associated access components. It also provides case-planning and physician-support services for complex procedures.

The company has a particularly strong reputation in fenestrated and customized repair. This position is valuable for juxtarenal and pararenal aneurysms where standard abdominal grafts do not provide an adequate sealing zone.

That said, customized manufacturing can involve longer planning and production cycles. Off-the-shelf branched competitors may have an advantage in urgent cases or hospitals seeking a more standardized inventory model.

Cook remains a clinically influential supplier. Its commercial position is strongest in high-complexity centers where physicians value configurable graft architecture and specialist case support.

Terumo Aortic

Terumo Aortic combines endovascular systems with a substantial surgical aortic graft portfolio. Its endovascular offering includes modular abdominal repair, thoracic repair, dissection-focused systems, and patient-specific fenestrated configurations. Its surgical range extends from the aortic root to thoracoabdominal reconstruction.

This combination supports hospitals that manage patients across open, hybrid, and fully endovascular pathways. It also gives the company relationships with vascular and cardiothoracic surgeons rather than limiting its commercial reach to interventional users.

In November 2025, Terumo Aortic began a pivotal U.S. study of a customized fenestrated abdominal platform for juxtarenal and suprarenal aneurysms. The study plans to enroll approximately 210 patients across as many as 45 sites, with follow-up extending for five years.

Its current strategic position is that of a broad aortic-care company preparing to strengthen its presence in the U.S. complex-EVAR segment.

Artivion

Artivion has traditionally been stronger in surgical aortic reconstruction, hybrid arch repair, and related cardiovascular implants. Its acquisition of Endospan in May 2026 added an FDA-approved endovascular arch platform to its portfolio.

The acquired system is designed for lesions involving the ascending aorta and aortic arch. It uses a modular configuration with an integrated branch for the brachiocephalic artery. The FDA approved the platform in April 2026 for specified high-risk patients.

This transaction gives Artivion a differentiated position. It can now address surgical, hybrid, and endovascular arch treatment through one commercial organization.

The company remains smaller than the largest diversified cardiovascular-device manufacturers. Still, its focus on aortic disease may allow faster specialization, concentrated physician engagement, and targeted portfolio development.

Endologix

Endologix is a focused abdominal-aortic supplier. Its commercial portfolio includes two differentiated EVAR platforms designed for specific aneurysm anatomies and sealing requirements. One system uses a conventional bifurcated configuration, while the other uses a polymer-assisted sealing approach near the renal arteries.

The company’s narrower portfolio can be both an advantage and a limitation. It enables concentrated investment in abdominal repair and specialized anatomical needs. However, it offers less exposure to thoracic, thoracoabdominal, and arch procedures than larger competitors.

Endologix is positioned as a specialist challenger rather than a full-aorta platform supplier. Its success depends on demonstrating durable outcomes and identifying patients who are not well served by conventional graft designs.

MicroPort Endovastec

MicroPort Endovastec is emerging as a significant China-based competitor. Its portfolio covers abdominal, descending thoracic, branched arch, and investigational multi-branch thoracic systems. The company has also expanded commercial use of its products across Asia, Europe, Latin America, and selected emerging markets.

Its competitive advantage is the ability to develop lower-profile and branched systems for anatomies that are important in Asian clinical practice. Domestic manufacturing also supports pricing flexibility in China and other cost-sensitive markets.

In March 2026, the company announced FDA Breakthrough Device Designation for an investigational three-branch thoracic platform intended to reconstruct the aortic arch and its major supra-aortic branches.

MicroPort Endovastec remains less established in the United States than Medtronic, Gore, or Cook. Yet its regulatory progress suggests that it intends to move beyond its current position as a regional manufacturer.

Competitive Benchmarking Matrix

Analyst assessment: Gore and Cook currently have the strongest positions in complex endovascular repair. Medtronic retains greater scale across routine abdominal and thoracic procedures. Terumo Aortic and Artivion are building broader positions that link endovascular technology with surgical aortic care.

Regional Landscape and Adoption Outlook

Adoption varies sharply by country. The device may be available, but that does not mean every hospital can use it. Complex endovascular repair requires high-resolution CT imaging, hybrid operating rooms, trained vascular teams, intensive care support, and reliable access to multiple implant sizes.

Reimbursement also changes the commercial picture. Countries with public or private coverage for complex graft configurations support broader adoption. Markets dominated by out-of-pocket expenditure remain concentrated in premium urban hospitals.

Indicative Regional Growth Outlook

The growth ranges are analyst estimates. They reflect procedure development, pricing, regulatory access, infrastructure, and the expected mix of standard and complex graft systems.

United States

The United States remains the largest individual commercial market. High implant pricing, established Medicare coverage, specialist vascular centers, and early access to approved complex technologies support its position.

The U.S. Preventive Services Task Force recommends one-time ultrasound screening for men aged 65–75 years who have smoked. Screening moves asymptomatic patients into surveillance and treatment pathways before rupture.

The country also has the clearest route for commercializing high-risk devices through the FDA premarket approval process. Recent approvals have expanded endovascular treatment into thoracoabdominal and arch anatomy.

The main adoption centers are large academic hospitals and integrated cardiovascular networks. California, Texas, Florida, New York, Massachusetts, Ohio, Pennsylvania, and the upper Midwest contain several major referral institutions.

Growth through 2035 will come from:

• Branched thoracoabdominal repair
• Aortic arch intervention
• Treatment of chronic dissection
• Greater use of image-fusion and digital case planning
• Referral of complex cases to regional centers of excellence

The constraint is not basic device availability. It is specialist capacity. Complex repairs can require long procedure times, multiple operators, intensive care, and repeated imaging follow-up.

Europe

Europe is a mature but fragmented market. Germany, the United Kingdom, France, Italy, Spain, the Netherlands, and the Nordic countries form the principal commercial cluster.

European centers have extensive experience with custom-made fenestrated and branched grafts. This has supported earlier use of complex configurations than in markets where only standard, nationally approved systems are routinely available.

The United Kingdom has an organized public AAA screening pathway that invites eligible men in their 65th year. A government review published in 2025 concluded that the UK screening programs contributed to reductions in AAA-related deaths.

Europe’s regulatory environment is more demanding under the Medical Device Regulation. Implantable Class III devices face notified-body assessment, clinical-evidence requirements, traceability obligations, and annual periodic safety reporting.

This may slow product renewal and increase compliance costs. It can also favor established manufacturers with mature clinical and regulatory teams.

Germany is likely to remain the largest national revenue contributor. The UK stands out for screening infrastructure. France and Italy maintain strong specialist centers, while the Netherlands and Nordic countries provide attractive environments for advanced clinical adoption despite smaller populations.

China

China is expected to be one of the fastest-growing national markets. Procedure access is moving beyond a small group of Beijing and Shanghai hospitals into provincial cardiovascular and vascular centers.

International companies remain important. Still, the competitive landscape is increasingly influenced by domestic manufacturers such as MicroPort Endovastec and LifeTech Scientific.

China’s NMPA approved an innovative domestically developed aortic covered-stent system in June 2025. MicroPort Endovastec also reported approvals and commercial use of locally developed branched arch systems during 2025.

Domestic products could reshape pricing. They may also improve access to device sizes and configurations developed around local anatomical requirements.

Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Chengdu, Wuhan, and Nanjing are expected to remain important adoption centers. Growth will gradually spread to large provincial hospitals.

The main constraints are procurement pressure, uneven physician experience, hospital-level variation in complex procedure capacity, and the need for long-term domestic clinical evidence.

Expert view: China’s opportunity is not only higher procedure volume. Local companies are moving into branched and arch systems. That may turn the country from an import-led market into an export-oriented innovation base.

India

India remains underpenetrated. Standard EVAR and TEVAR are available in major private and teaching hospitals, but adoption outside large cities is limited.

The strongest clinical markets are Delhi NCR, Mumbai, Chennai, Bengaluru, Hyderabad, Ahmedabad, Pune, and selected centers in Kerala and eastern India.

Imported implant prices, limited routine AAA screening, uneven vascular-surgeon availability, and out-of-pocket expenditure restrict wider use. Complex fenestrated and branched procedures are concentrated in a small number of tertiary institutions.

India regulates medical devices under the Medical Devices Rules. High-risk devices require central licensing, and imported devices require an import licence issued through the Central Licensing Authority. Clinical-investigation permission may also be required for investigational devices.

The market offers strong percentage growth because the current base is small. The clearest commercial opportunities are:

• Lower-profile standard abdominal systems
• Products suited to smaller access vessels
• Hospital inventory partnerships
• Tiered pricing for private and government institutions
• Physician training outside major metropolitan centers

Growth will remain tied to affordability. A technically advanced platform may generate little volume unless the supplier can support reimbursement, financing, or lower-cost procurement models.

Japan

Japan has a mature cardiovascular system, advanced imaging infrastructure, experienced aortic specialists, and a large older population. Device uptake is methodical and evidence-led.

The Pharmaceuticals and Medical Devices Agency approved an off-the-shelf thoracoabdominal branched system in November 2024. Japan also approved a branched thoracic platform that preserves flow to the left subclavian artery.

These approvals support continued movement from standard EVAR and TEVAR toward branch-preserving repair.

Tokyo, Osaka, Yokohama, Nagoya, Kyoto, Fukuoka, and Sapporo contain major treatment centers. National reimbursement supports access, although hospitals generally require strong domestic or international clinical evidence before changing established device preferences.

Revenue growth will be slower than in China or India because endovascular treatment is already well developed. The opportunity lies in higher-value complex procedures rather than rapid expansion of basic EVAR.

South Korea

South Korea has advanced tertiary hospitals and high-quality cardiovascular imaging. Seoul dominates complex aortic treatment, followed by major centers in Busan, Daegu, Daejeon, and Gwangju.

A range of abdominal, thoracic, iliac-branch, and thoracoabdominal systems is available in the country. Korean clinical education materials from 2025 list devices from major international suppliers across EVAR and TEVAR indications.

Domestic and Chinese-developed graft systems are also entering the market. MicroPort reported Korean use of a branched thoracic platform during 2025, following earlier approval of its abdominal graft system.

Adoption is supported by experienced physicians and national health coverage. However, emergency access differs by region. Recent Korean research has highlighted disparities in the treatment of ruptured abdominal aneurysms and the potential need for more centralized referral pathways.

The market will grow through complex referral centers rather than widespread community-hospital adoption.

Middle East

The Middle East is relevant, but demand is concentrated. Saudi Arabia and the United Arab Emirates lead regional adoption. Qatar, Kuwait, Israel, and selected hospitals in Turkey also contribute to advanced aortic treatment.

Saudi Arabia is investing in cardiovascular infrastructure as part of its health-system transformation. High-complexity procedures are concentrated in large government, military, university, and specialist hospitals in Riyadh, Jeddah, Dammam, and other major cities.

Medical devices must receive Saudi Food and Drug Authority listing or marketing authorization before being placed on the market. The pathway follows risk-based requirements and local quality-management obligations.

Government funding can support premium implants for eligible patients. Still, the market depends heavily on imported products, distributor capability, and supplier-managed inventory.

The UAE has a smaller population but strong private and government hospital infrastructure in Abu Dhabi and Dubai. Its role as a regional medical hub supports complex referrals from nearby countries.

Regional growth will be attractive in percentage terms. Yet total procedure volume will remain below the United States, Europe, China, and Japan.

Expert view: In emerging markets, commercial success will depend less on having the broadest catalogue and more on ensuring that the correct graft sizes, technical specialists, and procedural support are available when a case is scheduled.

Recent Developments, Opportunities and Restraints

Recent Developments

• November 2024 – Japan approved an off-the-shelf thoracoabdominal branched endovascular system. The platform preserves blood flow to visceral vessels and expands the treatment options available for patients who are difficult to manage through conventional surgical repair.
• June 2025 – China’s NMPA approved a domestically developed aortic covered-stent system from LifeTech Scientific. The approval supports the shift toward locally manufactured complex aortic devices and stronger domestic competition.
• November 2025 – Terumo Aortic enrolled the first patient in its U.S. pivotal fenestrated-EVAR study. The study covers juxtarenal and suprarenal aneurysms and plans to include approximately 210 patients at up to 45 clinical sites.
• April 2026 – The FDA approved Endospan’s modular aortic arch stent-graft system. The approval created a new endovascular option for selected high-risk patients with disease involving the ascending aorta and arch.
• May 2026 – Artivion completed its acquisition of Endospan. The transaction involved a net upfront purchase price of approximately $135 million and added an FDA-approved arch platform to Artivion’s aortic portfolio.

Opportunities and Business Insights

Complex Aortic Repair

Thoracoabdominal, juxtarenal, arch, and chronic-dissection procedures offer the strongest value-growth opportunity. These cases use more components and carry higher procedural revenue than routine abdominal EVAR.

Emerging-Market Expansion

China, India, Southeast Asia, and parts of the Middle East remain underpenetrated. Lower-profile systems, regional inventory hubs, physician training, and flexible pricing could unlock demand.

Digital Planning and Clinical Support

Automated CT segmentation, centerline measurements, virtual graft positioning, and standardized case-planning services could reduce preparation time. The winning commercial model may combine the implant with software and specialist planning support.

Market Restraints

• Complex grafts remain expensive and require advanced infrastructure.
• Regulatory approval demands long-term clinical and mechanical evidence.
• Endoleaks, migration, branch occlusion, and reintervention remain important follow-up concerns.
• Many patients remain unsuitable because of landing-zone, access-vessel, or branch anatomy.
• Procedures are concentrated among a limited number of highly trained physicians.